share_log

HC Wainwright & Co. Initiates Coverage On Acasti Pharma With Buy Rating, Announces Price Target of $2.4

Benzinga Real-time News ·  Dec 15, 2022 06:44

HC Wainwright & Co. analyst Oren Livnat initiates coverage on Acasti Pharma (NASDAQ:ACST) with a Buy rating and announces Price Target of $2.4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment